Our findings suggest that JAG1+ exosomes derived from regenerating liver tissue may serve as a promising cell-free therapeutic strategy to promote liver regeneration, particularly in clinical contexts such as acute liver injury, post-hepatectomy liver failure, and liver transplantation. This evidence concerns the gene JAG1 and liver failure.